Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid ...
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
- Associated Therapies
- -
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT02120469
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope Rancho Cucamonga, Rancho Cucamonga, California, United States
🇺🇸South Pasadena Cancer Center, South Pasadena, California, United States
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT02097238
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Study of Eribulin in Children With Cancer to Determine Safety
- First Posted Date
- 2014-03-10
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 3
- Registration Number
- NCT02082626
- Locations
- 🇺🇸
Jimmy Everest Center for Cancer and Blood Disorders in Children, Oklahoma City, Oklahoma, United States
Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 53
- Registration Number
- NCT02061085
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 201
- Registration Number
- NCT02037529
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States
🇺🇸Essentia Health NCI Community Oncology Research Program, Duluth, Minnesota, United States
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Prof. Wolfgang Janni
- Target Recruit Count
- 116
- Registration Number
- NCT02035813
- Locations
- 🇩🇪
University Hospital Ulm -Department of Gynecology, Ulm, Baden-Württemberg, Germany
Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT01961544
- Locations
- 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of
First Line Metastatic Breast Cancer Treatment (ESMERALDA)
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 61
- Registration Number
- NCT01941407
- Locations
- 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷Clinique Tivoli, Bordeaux, France
🇫🇷Centre Hospitalier d'Auxerre, Auxerre, France
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT01912963
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 86
- Registration Number
- NCT01908101
- Locations
- 🇺🇸
Skagit Valley Hospital, Mount Vernon, Washington, United States
🇺🇸Olympic Medical Center, Port Angeles, Washington, United States
🇺🇸Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.